Background: Tamoxifen remains important in the treatment and prevention of estrogen receptor-positive breast cancer.
Patients and methods:
We carried out a retrospective study on postmenopausal tamoxifen users for which germline DNA was available and at least one DET measurement was made between January 2000 and October 2011. Genotyping of 33 single nucleotide polymorphisms in CYP450 genes involved in tamoxifen metabolism was carried out using Sequenom MassARRAY. The association between these variants and TVU outcome (DET ≥5 mm) was assessed by proportional hazards regression.
Results: Data were available for 184 women: 47 with a DET of <5 mm on all ultrasounds and 137 with a DET of ≥5 mm on at least one ultrasound. The rs1800716 variant in CYP2D6 showed a statistically significant association with DET. In particular, mutant carriers of rs1800716 had an increased chance of having a DET of ≥5 mm (P = 0.0022, false discovery rate 0.0179). None of the other variants were associated with DET.
Conclusion:
Although mutant carriers of rs1800716 are characterized by reduced CYP2D6 enzyme activity and by low levels of endoxifen, we observed that mutant alleles of rs1800716 were associated with an increased chance of having a DET of ≥5 mm in postmenopausal women on tamoxifen. We conclude that the increase in endometrial thickness seen under tamoxifen cannot be used as a marker for favorable genotypes.
Clinical Trial Number: B32220084284.
Key words: breast cancer, tamoxifen, endometrial thickness, cyp2d6 introduction Tamoxifen, a selective estrogen-receptor modulator (SERM), was originally developed for contraceptive purposes, but is nowadays important in the treatment and prevention of estrogen receptor-positive breast cancer. Tamoxifen is prescribed to breast cancer patients at all ages and relatively well tolerated. It binds to nuclear estrogen receptors, with tissue-specific agonist-antagonist activities that have been widely characterized. In particular, tamoxifen acts as an estrogen antagonist on mammary cancer cells where it inhibits cell proliferation and leads to cell death [1] . It is estimated that tamoxifen saved lives of more than a million women. On the other hand, in the postmenopausal endometrium, tamoxifen can act as an estrogen agonist, leading to endometrial hyperplasia, cysts and polyps [1, 2] . Women taking tamoxifen have a higher risk of developing endometrial cancer and uterine sarcoma, which has been estimated to occur in about 1 per 1000 users per year [3] .
Tamoxifen is metabolized to the more active metabolite endoxifen by several of the cytochrome P450 (CYP450) enzymes, including CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 [4, 5] . Pharmacogenetic studies of tamoxifen metabolism have shown that the CYP2D6 poor metabolizer phenotype, mostly defined by the presence of a mutant rs1800716 genotype, can be used to identify patients with reduced tamoxifen metabolism and to predict poor responsiveness to tamoxifen in terms of disease recurrence [6] . However, in several clinical investigations, results were not confirmed and evidence for the use of CYP2D6 genotyping proved inconclusive [7] . With CYP2D6 pharmacogenetic testing now available, there is uncertainty among patients, health-care providers, health authorities and insurers about its utility for patient care [8] [9] [10] [11] [12] [13] .
Alternatively, it has been proposed that the presence of sideeffects due to tamoxifen, including hot flashes, might serve as a biomarker for tamoxifen efficacy. Ultrasonography studies of the endometrium in asymptomatic women have shown that a minority of postmenopausal patients on tamoxifen do not have the typical tamoxifen-induced increase in endometrial thickness [3] . Possibly, there is an association between patients not having the typical tamoxifen-like increased endometrial thickness and inadequate tamoxifen metabolism, for instance, caused by pharmacogenetic variants in CYP enzymes. As such, endometrial thickening in tamoxifen users could serve as a biomarker for worse disease control among tamoxifen-treated, postmenopausal hormone receptor-positive breast cancer patients.
So far, only a few studies assessed association between genetic variants in CYP450 enzymes and the increase in endometrial thickness in tamoxifen users. Okishiro et al. [14] found no association between variants in CYP2D6 and CYP2C19 and endometrial thickness in a Japanese population; however, only a limited number of variants were assessed (rs1065852 in CYP2D6, and rs4244285 and rs4986893 in CYP2C19) and the number of patients participating in this study was small (n = 21). We previously also published a limited series of case reports describing women having the typical endometrial changes seen under tamoxifen despite being homozygous for rs1800716 [15] . In this study, we therefore assessed the influence of genetic variants in tamoxifen-metabolizing enzymes on endometrial appearance by assessing the double endometrial thickness (DET) in a large series of 184 postmenopausal breast cancer patients.
methods
Patients were selected from the Leuven Multidisciplinary Breast Center (LMBC) database that contains extensive clinical data from all new breast cancer patients diagnosed at University Hospital Leuven since 2000 [16] . Eligibility criteria for the current study were: women who were followed at the LMBC for an invasive or in situ breast cancer, postmenopausal status (i. e. >1 year of amenorrhea at first ultrasound), intact uterus, at least one DET measurement available in the gynecology ultrasound database between January 2000 and October 2011, taking tamoxifen 20 mg daily for at least 3 months at the moment the ultrasound was carried out, and germline DNA available in the LMBC biobank. In total, 184 women fulfilled these eligibility criteria. Electronic charts of all eligible women were reviewed and all participating women were classified into two groups according to DET measured by transvaginal ultrasound (TVU): a first category consisting of women with a DET of <5 mm on all ultrasounds and a second consisting of women with a DET of ≥5 mm on at least one ultrasound. This cutoff is widely used to determine whether further investigation is recommended [17, 18] . DET was measured according to published guidelines [19] . Blood sampling, genetic analysis and collection of patient ultrasound data were approved by the local Ethical Committee. All patients provided written informed consent for the LMBC biobank.
Germline DNA samples of the LMBC biobank were analyzed at the Vesalius Research Center using the iPLEX technology on a MassARRAY Compact Analyzer (Sequenom, Inc., San Diego, CA, USA) as described previously [20] . Initially, a total of 33 variants in CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A5, which are all enzymes important for metabolizing tamoxifen into endoxifen, were genotyped. More specifically, the following variants were genotyped: rs2279343, rs3211371, rs3745274 and rs34223104 in CYP2B6, rs1057910, rs28371686 and rs9332131 in CYP2C9, rs4244285, rs17878459, rs4986893, rs28399504, rs56337013, 395G>A, 19294T>A, rs41291556, rs17884712 and rs11188072 in CYP2C19, 1584C>G, rs4986774, rs1135824, rs1800716, rs5030655, rs5030866, rs5030867, rs5030865, rs5030656, rs1065852, rs5030863, rs28371706, rs28371725, rs16947 and the deletion in CYP2D6 and rs776746 in CYP3A5 (Table 1) .
Next, we combined individual single nucleotide polymorphism (SNP) genotypes and developed for each of the six genes a genetic score predicting how well tamoxifen is metabolized in each patient. In particular, women carrying no or only a single allele that increased or decreased tamoxifen metabolism were classified as extensive metabolizers (EMs). Women carrying alleles with increased activity were also classified as EMs, as a separate group of ultrarapid metabolizers would be too small due to the rare occurrence of ultrarapid metabolizer alleles. Furthermore, women having two alleles with decreased metabolizing activity or one allele with decreased activity in combination with a nonfunctional allele were classified as intermediate metabolizers (IMs), whereas women carrying two nonfunctional alleles were assigned a poor metabolizer (PM) phenotype. All continuous data were summarized using means and standard deviations, or medians and interquartile ranges in case data deviated significantly from a normal distribution. Categorical data were summarized using observed frequencies and percentages. Hardy-Weinberg equilibrium was assessed for each of the genotyped SNPs using a standard χ 2 with one degree of freedom. The association between variants and outcome (DET ≥5 mm) was assessed by means of a proportional hazards regression for interval censored data as described by Farrington [21] , whereby DET of ≥5 mm was assumed to have occurred in the interval between the last ultrasound with a DET of <5 mm and the first with a DET of ≥5 mm. Only genetic variants with an allele frequency >5% were used in this analysis. To correct for the fact that multiple genetic markers were assessed, false discovery rates (FDRs) were calculated.
results
Overall, 184 postmenopausal women treated with tamoxifen met the eligibility criteria of this study. Of these, 47 patients exhibited a DET of <5 mm on all ultrasounds and 137 presented with a DET of ≥5 mm on at least one ultrasound. Tumor characteristics of the 176 patients with an invasive tumor are summarized in Table 2 . The other eight patients received tamoxifen for an in situ tumor. Median age at diagnosis was 50 and 55 years, and the median duration of tamoxifen therapy at first ultarsound was 15 and 13 months in the group with a DET of <5 and ≥5 mm, respectively. Germline DNA from each of these 184 patients was genotyped for selected 33 genetic variants in CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A5. Genotyping failed for four genetic variants: rs3745274 in CYP2B6, rs17884712 in CYP219 and rs1065852 and the deletion in CYP2D6. Genotype frequencies of each variant were within the Hardy-Weinberg equilibrium (P > 0.05), except for rs5030656 in CYP2D6 (P-value 0.0003). The latter variant was therefore removed from further analysis. Only eight variants exhibited a minor allele frequency (MAF) of >5%, i.e. rs2279343 and rs3211371 in CYP2B6, rs1057910 in CYP2C9, rs4244285 and rs11188072 in CYP2C19, rs1800716 and rs16947 in CYP2D6 and rs776746 in CYP3A5. Owing to our limited study population, which is too small to reasonably detect statistically significant associations for variants with an MAF of <5, we limited our analysis in this study to these eight variants only.
Overall, one variant showed a statistically significant association with DET while surviving correction for multiple testing using the FDR statistic (Table 3 ). In particular, variant alleles of rs1800716 in CYP2D6 were associated with a DET of ≥5 mm (uncorrected P = 0.0022; FDR 0.018). Heterozygous carriers of the mutant rs1800716 allele exhibited a hazard ratio (HR) of 1.88 (CI = 1.276-2.768), whereas homozygous carriers of the mutant rs1800716 allele had an HR of 2.786 (CI = 0.988-7.858) to develop a DET of ≥5 mm upon tamoxifen. None of the other genetic variants showed a correlation with outcome ( Table 3) . The combination of individual SNP genotypes into a genetic score predictive of tamoxifen metabolism failed to observe any substantial associations (Table 4) .
Of the 137 women with a DET of ≥5 mm on at least one TVU assessment, 78.8% had a tamoxifen-like endometrium [19] , endometrial cysts and polyps were present in 85.4% and 10.2% of the women, respectively; 18.2% reported postmenopausal bleeding. Of the 47 women with a DET of <5 mm, the TVU showed a tamoxifen-like endometrium in 36.2% of the women according to the gynecologist, endometrial cysts and polyps were present in 34.0% and 0.0% of the women, respectively; only 2.1% presented with postmenopausal bleeding.
discussion
The rs1800716 variant is known to significantly lower serum endoxifen concentration and has been associated with reduced tamoxifen efficacy in several studies. Here, we demonstrate a significant association between rs1800716 and DET in postmenopausal women receiving tamoxifen treatment. Carriers of mutant rs1800716 alleles, thus, have an increased chance of having a DET of ≥5 mm on TVU. These observations did not confirm our initial hypothesis, namely that carriers of PM variants do not have the typical tamoxifen-induced increase in endometrial thickness, whereas the antagonistic effect on mammary cancer cells is mainly mediated by the levels of endoxifen. It is not known which tamoxifen metabolites are responsible for the estrogen-like activity on the endometrium, it could be tamoxifen itself or other metabolites, explaining these results. It is known, however, that several metabolites can be formed in the endometrium as it contains CYP450 enzymes [22] . As we observed that women homozygous mutant for the rs1800716 variant have an increased chance of having a DET of ≥5 mm, and given the fact that these women are also PMs for tamoxifen, we would also expect to observe a substantial correlation between the PM group and DET. However, this was not the case. This can be explained by a misclassification of the patients in the metabolizer subgroups. First of all, not every genetic variant in every CYP450 enzyme was genotyped and, as such, some PMs could have been missed. We feel, however, that this would not play an important role since only rare genetic variants leading to an inactive enzyme failed genotyping. More importantly, we defined women as PMs when carrying two inactive alleles, meaning that women being compound heterozygous for inactive alleles were also considered PM. However, a proportion of these women could still display a certain level of CYP2D6 activity if both alleles are located on the same chromosome. We therefore conclude that the present model for defining the phenotypes does not correctly reflect the genotypes.
Due to the retrospective nature of the study, several limitations have to be taken into account. It is possible that some We limited this misclassification by including only women at least 3 months on tamoxifen at the time of the ultrasound, as tamoxifen-induced changes to the endometrium begin soon after starting with tamoxifen. In addition, the above analyses methods assume that all censoring times are non-informative and independent. However, it is possible that these assumptions are violated due to the fact that some ultrasounds were done because of, for example, symptoms related to an increased DET. Furthermore, this analysis does not allow us to correct for differences in DET before administration of tamoxifen, since no DET data before administration are available. Data on weight at first ultrasound, tamoxifen compliance and co-intake of CYP2D6 inhibitors, interfering with tamoxifen metabolization, were not available and were therefore not taken into account. Our findings are relevant to report as no other study, so far, investigated the relation between tamoxifen metabolization and DET in such a large population. Since tamoxifen-related sideeffects or symptoms have been linked with its efficacy, our study is important as it demonstrates that a thickened endometrium does not equal EM or IM status and should not be used as a biomarker for tamoxifen's activity. In the future, we plan to validate our findings in the prospective CYPTAM-BRUT 3 study, in which endometrial thickness is measured at baseline and after 6 months on tamoxifen and will be combined with genotype data and serum endoxifen levels. 
